Atai Life Sciences N.V. (ATAI, Financial), a clinical-stage biopharmaceutical company, observed a significant stock movement with a 6.13% rise in share price, reaching $1.13. The trading volume stood at 566,305 shares, with a turnover rate of 0.34% and a price fluctuation of 4.72%.
Recent financial reports reveal that ATAI generated a revenue of $273,000, with a net loss of $57.31 million, and an earnings per share of -$0.36. The company's gross profit was noted as $191,000, with a price-to-earnings ratio of -3.07. Impressively, all seven analysts covering the stock recommend buying ATAI, with no holds or sells.
In the broader biotechnology sector, shares declined by 0.20%. However, some related stocks showed significant gains, including Lexaria Bioscience Corp, Cardio Diagnostics Holdings Inc, and Tc Biopharm (Holdings) Plc. Notably active stocks with high turnover rates include Aditxt, Inc., Theriva Biologics, Inc., and Seelos Therapeutics, Inc.
Atai Life Sciences focuses on developing innovative treatments for mental health disorders. Their product candidates include therapies using compounds like psilocybin, R-ketamine, ibogaine, and others. The company operates in the United States and Germany.
